English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
 Local TagsRelease HistoryDetailsSummary
  Multiple event activation of a generic prodrug trigger by antibody catalysis

Shabat, D., Rader, C., List, B., Lerner, R. A., & Barbas, C. F. (1999). Multiple event activation of a generic prodrug trigger by antibody catalysis. Proceedings of the National Academy of Sciences of the United States of America, 96(12), 6925-6930. doi:10.1073/pnas.96.12.6925.

Item is

 

show all hide all

Basic

show hide
Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0014-A4EB-A Version Permalink: https://hdl.handle.net/21.11116/0000-0007-6186-4
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Shabat, Doron1, Author
Rader, Christoph1, Author
List, Benjamin1, Author           
Lerner, Richard A.1, Author
Barbas, Carlos F.1, Author
Affiliations:
1The Skaggs Institute for Chemical Biology and the Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA., ou_persistent22              

Content

show
hide
Free keywords: -
 Abstract: Chemotherapeutic regimes are typically limited by nonspecific toxicity. To address this problem we have developed a broadly applicable drug-masking chemistry that operates in conjunction with a unique broad-scope catalytic antibody. This masking chemistry is applicable to a wide range of drugs because it is compatible with virtually any heteroatom. We demonstrate that generic drug-masking groups may be selectively removed by sequential retro-aldol–retro-Michael reactions catalyzed by antibody 38C2. This reaction cascade is not catalyzed by any known natural enzyme. Application of this masking chemistry to the anticancer drugs doxorubicin and camptothecin produced prodrugs with substantially reduced toxicity. These prodrugs are selectively unmasked by the catalytic antibody when it is applied at therapeutically relevant concentrations. We have demonstrated the efficacy of this approach by using human colon and prostate cancer cell lines. The antibody demonstrated a long in vivo half-life after administration to mice. Based on these findings, we believe that the system described here has the potential to become a key tool in selective chemotherapeutic strategies.

Details

show
hide
Language(s): eng - English
 Dates: 1999-04-081999-06-08
 Publication Status: Issued
 Pages: 6
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: DOI: 10.1073/pnas.96.12.6925
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Proceedings of the National Academy of Sciences of the United States of America
  Other : PNAS
  Other : Proceedings of the National Academy of Sciences of the USA
  Abbreviation : Proc. Natl. Acad. Sci. U. S. A.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Washington, D.C. : National Academy of Sciences
Pages: - Volume / Issue: 96 (12) Sequence Number: - Start / End Page: 6925 - 6930 Identifier: ISSN: 0027-8424
CoNE: https://pure.mpg.de/cone/journals/resource/954925427230